10 assets in Neuromuscular Disease

Therapeutic assets addressing Neuromuscular Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Apitegromab Neuromuscular Disease	Scholar Rock, Inc.	P3	BB (69)
Aoc 1044 Neuromuscular Disease	Avidity Biosciences, Inc.	P3	B (60)
Deramiocel Neuromuscular Disease	Capricor Inc.	P3	B (60)
Nexiguran Ziclumeran Neuromuscular Disease	Intellia Therapeutics	P3	B (60)
Taldefgrobep Alfa Neuromuscular Disease	Biohaven Pharmaceuticals, Inc.	P3	B (60)
Zeleciment Rostudirsen Neuromuscular Disease	Dyne Therapeutics	P3	B (60)
Nusinersen Neuromuscular Disease	Scholar Rock, Inc.	P2	CCC (53)
Risdiplam Neuromuscular Disease	Scholar Rock, Inc.	P2	CCC (53)
Sat-3247 Neuromuscular Disease	Satellos Bioscience, Inc.	P2	CCC (53)
Bioactivated Gra For Adult Patients Neuromuscular Disease	IRCCS Centro Neurolesi Bonino Pulejo	N/A	NR ()